HOBOKEN, NJ, April 05, 2012 (Press-News.org) Niiki Pharma Inc. announced the presentation of preclinical data for its novel anti-cancer compound, NKP-2235, at the American Association for Cancer Research (AACR) Annual Meeting held in Chicago, Illinois. NKP-2235 is a first-in-class compound, and the first highly orally bioavailable gallium-based anti-cancer agent.
This breakthrough in cancer research is significant because, although other companies have tried developing gallium-based anti-cancer compounds before, they could not maintain therapeutic dosages safely and effectively in vivo.
"Developing a highly orally bioavailable gallium-based anti-cancer agent that stays intact and targets tumors has been a holy grail to those who have worked with gallium in the past," stated Dr. Hooshmand Sheshbaradaran, CEO of Niiki Pharma.
NKP-2235 is a novel agent that targets the endoplasmic reticulum. In laboratory studies, NKP-2235 has demonstrated single agent activity against multiple tumor types, including those resistant to chemotherapy. The data presented at AACR show that NKP-2235 also has synergistic activity when combined with other chemotherapy agents.
"The distinctive pattern of tumor cell death and the broad single agent activity of NKP-2235 make this a very interesting agent. The synergism data suggest that NKP-2235 will also work well in multi-agent chemotherapy regimens," said Dr. Angela Ogden, Chief Medical Officer at Niiki Pharma.
Niiki Pharma has obtained IND approval from the FDA and IRB approval to start the single agent Phase I trial on NKP-2235 at Indiana University's Melvin and Bren Simon Cancer Center in Indianapolis, Indiana. Companion diagnostics will be developed in parallel to enable NKP-2235 to be targeted to patients who can most benefit from treatment.
About NKP-2235
NKP-2235 is the second most advanced compound in Niiki Pharma's novel pipeline. NKP-2235 is a first-in-class orally available compound that targets the endoplasmic reticulum with a unique pattern of tumor cell killing. Independent of its anti-tumor activity, it can also prevent bone breakdown. NKP-2235 IND has been cleared and a Phase I trial will be initiated shortly. NKP-2235 was originally discovered by Professor Bernhard Keppler, University of Vienna, Austria.
About Niiki Pharma Inc.
Niiki Pharma (www.niikipharma.com) is a development focused oncology company specializing in first-in-class cancer treatments directed at novel tumor targets and related companion diagnostics.
Contacts
For Media Relations: Carolyn Rhinebarger, carolyn@luminovas.com, +1-919-604-4053.
For Investor Relations and Partnering: Ali Ardakani, ardakani@niikipharma.com, +1-201-238-2885
Niiki Pharma Presents Data on NKP-2235, the First Highly Orally Bioavailable Gallium-Based Anti-Cancer Agent
Niiki Pharma announced the presentation of preclinical data at the American Association for Cancer Research Annual Meeting in Chicago, Illinois for its novel compound, NKP-2235, the first highly orally bioavailable gallium-based anti-cancer agent.
2012-04-05
ELSE PRESS RELEASES FROM THIS DATE:
The Mash House Brewery Named A Designated Brewer On Hand For Brewgaloo Craft Beer Festival
2012-04-05
Dean Ogan, owner of Rocky Top Hospitality (http://www.rockytophospitality.com), has announced that its brewery, The Mash House, will be one of the designated brewers on hand at the Brewgaloo beer festival on Saturday, April 28 from 3 p.m. to 9 p.m. in downtown Raleigh's City Plaza. Bringing together local craft brewers, the Brewgaloo festival encourages consumers to eat, drink, purchase and think with a local mindset. Sponsored by Shop Local Raleigh, an organization in support of locally-owned independent businesses, Brewgaloo will include local breweries as well as local ...
Second Wind Takes Certified Account Executive College To Chicago, IL, April 17-18, 2012
2012-04-05
"As the economy moves into recovery, company marketing budgets will begin to open up. Advertising and marketing firms need to position their people and business strategies to take advantage of the resurgence in marketing activity," said Laurie Mikes, COO of Second Wind, a leading content, advice and service provider dedicated to the advertising and marketing industry. "Retaining accounts, picking up new accounts, successful strategic planning and writing winning new business proposals are critical to midsize and small advertising agencies, especially as the ...
Aitech's Flexible COTS Integrated Subsystem Functions Out of the Box
2012-04-05
Aitech Defense Systems Inc., a pioneer in true embedded and mission critical computing technologies for environmentally-demanding military, defense and aerospace applications, now offers the highly-integrated, compact RediBuilt rugged COTS computer that boots and executes your real-time operating system right out of the box. This flexible computer can accommodate either Intel or Freescale processors as well as a CompactPCI or OpenVPX backplane in a condensed package measuring less than 0.22 ft3, comparable in volume to a 1/4 ATR Short enclosure.
Designed to TRL 9 (Technical ...
Mims Distributing Selects MMI Public Relations As Agency Of Record
2012-04-05
Patty Briguglio, president of MMI Public Relations (http://www.mmipublicrelations.com), a Raleigh-based full-service public relations firm, has announced that the firm has been named the public relations agency of record for Mims Distributing Company (http://www.mimsdist.com), a beer distributor that services a nine-county area in and around the Triangle. MMI will assist Mims Distributing to generate heightened positive visibility for the company, its employees and its community outreach within the Triangle, and eventually the region and nation, through traditional and ...
You Can Protect Assets by Transferring Them to a Trust
2012-04-05
You Can Protect Assets by Transferring Them to a Trust
Among the various estate-planning tools, trusts are perhaps the most effective in protecting assets. Wills provide a method of distributing your assets when you die, while trusts are legal entities that hold them and keep them safe. Credit shelter trusts, generation-skipping trusts and discretionary spendthrift trusts are especially useful because they generally cannot be accessed by creditors or former spouses.
Claims by Creditors, Ex-Spouses
If you have an ownership interest in a business, for example, it ...
Loftware Print Server v10.0 Acheives GS1 US Certification
2012-04-05
Loftware, the global leader in Enterprise Lifecycle Printing (ELP) software has successfully achieved the highly acclaimed GS1 Certification for the Loftware Print Server v10.0. As a long-time GS1 US Solution Partner, Loftware has worked alongside GS1 for over 10 years supporting the international GS1 standards and guidelines for barcode label printing. Attaining GS1 US Certification of Loftware Print Server 10.0 underscores the ongoing commitment to offer customers support for the latest compliance standards they have grown to expect from Loftware.
GS1, an international ...
Stickleback genome holds clues to adaptive evolution
2012-04-05
Scientists searching for genetic clues to vertebrate evolution have long been fascinated by the tiny marine stickleback fish, known for its ability to adapt and thrive in salty oceans or freshwater streams around the world. Now, a team of researchers from the Broad Institute and Stanford University has analyzed the entire genetic sequence of 21 threespine sticklebacks and identified which regions of the genome regulate their ability to adapt to such markedly different environments. The findings appear in the April 5 issue of Nature.
"Sticklebacks are essentially the 'Darwin's ...
Scientists uncover multiple faces of deadly breast cancer
2012-04-05
An international team of scientists, including four at Simon Fraser University, has made a discovery that will change the way the most deadly form of breast cancer is treated.
The journal Nature has just published the team's findings online in the paper The clonal and mutational evolution spectrum of primary triple negative breast cancers.
The study is the largest genetic analysis of what were thought to be triple negative breast cancer tumours.
The 59 scientists involved in this study expected to see similar gene profiles when they mapped on computer the genomes ...
Arsenic turns stem cells cancerous, spurring tumor growth
2012-04-05
Researchers at the National Institutes of Health have discovered how exposure to arsenic can turn normal stem cells into cancer stem cells and spur tumor growth. Inorganic arsenic, which affects the drinking water of millions of people worldwide, has been previously shown to be a human carcinogen. A growing body of evidence suggests that cancer is a stem-cell based disease. Normal stem cells are essential to normal tissue regeneration, and to the stability of organisms and processes. But cancer stem cells are thought to be the driving force for the formation, growth, and ...
New forage plant prepares farmers for climate changes
2012-04-05
Sorghum, or durra, is an important forage crop in many countries, for example the USA, Africa, China and Australia.
The plant is grown instead of corn because it produces more biomass and better withstands long periods of drought.
However, when exposed to drought, the sorghum plant produces large amounts of dhurrin, which forms toxic cyanide, i.e. Prussic acid.
Forced to discard crops
Farmers thus face a big dilemma. During a period of drought when they most need food for their animals, they are often forced to discard their sorghum because they do not know how ...
LAST 30 PRESS RELEASES:
Plant Physiology is Searching for its Next Editor-in-Chief
Clothes dryers and the bottom line: Switching to air drying can save hundreds
New insights into tRNA-derived small RNAs offer hope for digestive tract disease diagnosis and treatment
Emotive marketing for sustainable consumption?
Prostate cancer is not a death knell, study shows
Unveiling the role of tumor-infiltrating immune cells in endometrial carcinoma
Traditional Chinese medicine unlocks new potential in treating diseases through ferroptosis regulation
MSU study pinpoints the impact of prenatal stress across 27 weeks of pregnancy
Biochemist’s impact on science and students honored
ELF4: A key transcription factor shaping immunity and cancer progression
Updated chronic kidney disease management guidelines recommend SGLT2 inhibitors regardless of diabetes or kidney disease type
New research explores how AI can build trust in knowledge work
Compound found in common herbs inspires potential anti-inflammatory drug for Alzheimer’s disease
Inhaled COVID vaccine begins recruitment for phase-2 human trials
What’s in a label? It’s different for boys vs. girls, new study of parents finds
Genes combined with immune response to Epstein-Barr virus increase MS risk
Proximity and prejudice: Gay discrimination in the gig economy
New paper suggests cold temperatures trigger shapeshifting proteins
Reproductive justice–driven pregnancy interventions can improve mental health
Intranasal herpes infection may produce neurobehavioral symptoms, UIC study finds
Developing treatment strategies for an understudied bladder disease
Investigating how decision-making and behavioral control develop
Rutgers researchers revive decades-old pregnancy cohort with modern scientific potential
Rising CO2 likely to speed decrease in ‘space sustainability’
Study: Climate change will reduce the number of satellites that can safely orbit in space
Mysterious phenomenon at center of galaxy could reveal new kind of dark matter
Unlocking the secrets of phase transitions in quantum hardware
Deep reinforcement learning optimizes distributed manufacturing scheduling
AACR announces Fellows of the AACR Academy Class of 2025 and new AACR Academy President
TTUHSC’s Graduate School of Biomedical Sciences hosts 37th Student Research Week
[Press-News.org] Niiki Pharma Presents Data on NKP-2235, the First Highly Orally Bioavailable Gallium-Based Anti-Cancer AgentNiiki Pharma announced the presentation of preclinical data at the American Association for Cancer Research Annual Meeting in Chicago, Illinois for its novel compound, NKP-2235, the first highly orally bioavailable gallium-based anti-cancer agent.